Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and pharmacokinetics of OPA-15406 ointment in healthy adult males
jRCT2080222706Phase 1
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of difamilast (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety of OPA-15406 ointment and Pharmacokinetics of OPA-15406.
02
Drugs
difamilast
Beyond the preview
Go deeper on jRCT2080222706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222706.